Improvements in clinical assessment have occurred since the last published recommendations on the diagnosis and treatment of acute promyelocytic leukemia in 2013. Here, a committee of specialists of the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy presents a comprehensive review on the current knowledge, focusing on the advances in diagnosis, risk assessment, and frontline and salvage therapy. The concept of urgent diagnosis is explored as well as the management of critical situations such as coagulopathy and differentiation syndrome. Recent adjustments in risk stratification based on white blood cell counts only are presented together with the incorporation of chemo-free regimens for non-high-risk patients. Special conditions such as acute promyelocytic leukemia in children, the elderly and pregnant women are discussed. Finally, acute promyelocytic leukemia is presented as a highly curable disease because of the real possibility of targeted therapy towards differentiation, and, paradoxically, as a serious and urgent condition that deserves prompt recognition and management to avoid early mortality.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11451342 | PMC |
| http://dx.doi.org/10.1016/j.htct.2024.05.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Study on clinical features of early death in older patients with acute promyelocytic leukemia.
Ann Hematol
December 2024
Key Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, People's Republic of China.
This study aimed to analyze the baseline clinical characteristics, as well as the clinical features and risk factors of early death (ED) in older patients with acute promyelocytic leukemia (APL). A retrospective analysis was conducted on 198 consecutive older patients (age ≥ 50 years) with newly diagnosed APL who received arsenic trioxide alone as induction therapy, with 354 younger patients (age < 50 years) as controls. Ten easily obtainable clinical parameters were selected.
View Article and Find Full Text PDFA distinct subgroup of AML resembling the APL immunophenotype is associated with DIC.
BMC Cancer
December 2024
Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Background: The complexity of acute myeloid leukemia (AML) is increasingly recognized through the identification of distinct subgroups, including those with an APL-like immunophenotype characterized by the absence of CD34 and HLA-DR expression, which is widely recognized as a representative immunophenotype in acute promyelocytic leukemia (APL). This study sought to understand the clinical, molecular, and prognostic differences between AML patients with and without this phenotype.
Methods: This study retrospectively analysed 191 de novo non-M3 AML patients and identified 32 patients with the CD34HLA-DR phenotype resembling APL-like immunophenotype, considered as the experimental group.
Correction: JSH practical guidelines for hematological malignancies, 2023: leukemia-2-acute promyelocytic leukemia (APL).
Int J Hematol
December 2024
Department of Hematology, Saiseikai Yokohama Nanbu Hospital, 3-2-10 Konandai, Konan-ku, Yokohama, Kanagawa, 234-0054, Japan.
Nuclear receptor profiling for subtype classification and as prognostic markers in 33 cancer types.
Discov Oncol
December 2024
Laboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Nuclear receptors, a group of 48 transcription factors that regulate a multitude of processes within our body, have long been employed as diagnostic markers or therapeutic targets in breast cancer, prostate cancer, and acute promyelocytic leukemia. Unfortunately, no comprehensive investigation has been conducted on their significance in other cancer types. The current study aimed to explore novel diagnostic markers by classifying nuclear receptors according to their expression patterns based on transcriptome data from The Cancer Genome Atlas on 10,071 tumor samples across 33 cancer types and investigating their association with genetic mutations, histological types, and prognosis.
View Article and Find Full Text PDFATRA-induced NEAT1 upregulation promotes autophagy during APL cell granulocytic differentiation.
PLoS One
December 2024
Department of Hematology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Aims: Acute promyelocytic leukemia (APL) progresses quickly and often leads to early hemorrhagic death. Treatment with all-trans retinoic acid (ATRA) promotes differentiation of APL cells and clinical remission, making APL a potentially curable malignancy. Understanding how ATRA works may lead to new treatments for other types of leukemia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!